A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

To be considered for this study, you would generally need to be an adult or a teenager aged 12 or older. A key requirement is that you must have been diagnosed with chronic eczema on your hands and/or feet for at least a year. The eczema needs to be affecting at least two areas (like your left hand and right foot) and be considered moderate to severe by the research doctors.

Another important point is that your eczema should cause noticeable itching, and previous treatments applied to the skin, such as creams or ointments, haven't worked well for you in the last six months, or you haven't been able to use them for medical reasons.

There are also some reasons why you might not be able to join. For example, if your hand or foot rash is caused by an allergic reaction to something you've touched (called allergic contact dermatitis) that shows up on a patch test, or if doctors suspect it's a different type of eczema triggered by proteins, then this study might not be suitable for you.

If you decide to take part, the study will last for up to 32 weeks, which is about 7 to 8 months. Initially, there will be a 6-week 'screening' period where doctors will check if you're a good fit for the study. Following this, you'll enter a 16-week 'treatment period' where you'll receive either lebrikizumab or the placebo. After you've finished taking the study medicine, there will be a final check-up visit about 12 weeks later to make sure you're doing well and to see if there are any lasting effects.